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PRESCRIBING PRACTICES IN LONG-TERM CARE: 
INVISIBLE INFLUENCES 
Diane Feeney Mahoney*, Tammy McNeill**, MJ Henderson*** 
INTRODUCTION 
Adults over age sixty-five are the greatest consumers of 
prescription drugs, taking one third of prescription medications 
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prescribed in the U.S.1  Older adults in long-term care settings 
are more likely to be in poorer health than their community-
dwelling counterparts.  Nursing home residents, on average, 
take ten different medications daily for a range of co-morbid 
health conditions and still rate their health as either fair or poor.2 
The purpose of this paper is to provide an overview of the 
existing influences on prescribing patterns in the long-term care 
setting, and to inform and alert the legal community about 
issues that affect treatment of geriatric clients in these settings. 
Older adults are at increased risk for adverse drug events 
due to consumption of multiple medications and age-related 
physiological alterations in the absorption and elimination of 
medications.  Other more invisible influences, such as 
pharmaceutical industry marketing techniques, also affect 
prescribing practices in long-term care settings.  Currently, 
pharmaceutical marketing activities are under scrutiny for 
influencing consumer demand and physicians’ drug decision 
making.  The advent of nurse practitioner (NP) prescribers offers 
new insights into additional key influences on drug selection 
and utilization.  Examination of a range of seemingly invisible 
influences is explored to bring to light the complexities of 
geriatric prescribing in long-term care.  (See Figure 1.)  Ways to 
optimize safe, cost-effective prescribing approaches for older 
adults will also be discussed.   
AGE-RELATED PHYSIOLOGICAL CHANGES THAT AFFECT 
PRESCRIBING 
PHARMACODYNAMICS 
Pharmacodynamics relates to the physiological and  
 
 1.  Lisa C. Hutchison, Biomedical Principles of Aging, in FUNDAMENTALS OF 
GERIATRIC PHARMACOTHERAPY 53, 62 (Lisa C. Hutchison & Rebecca B. Sleeper eds., 
2010). 
 2.  Richard G. Stefanacci, Medicare Reform’s Impact on Long-Term Care, 5 
JAMDA 418, 418 (2004). 
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biochemical effects that drugs have on the body.  The 
pharmacodynamic properties of prescription drugs are altered 
in the older adult due to age-related changes within multiple 
body systems.3  For example, the cardiovascular system of the 
older adult experiences diminished capacity of the baroreceptors 
to respond to drops in blood pressure, making individuals more 
susceptible to orthostatic hypotension, and to respond to 
lowered blood pressure that can result from changes in posture, 
 
 3.  See Hutchison, supra note 1, at 63. 
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such as standing, that can be exacerbated by many classes of 
anti-hypertensive medications.4  The older adult is also more 
likely to experience isolated systolic hypertension due to loss of 
elasticity of blood vessels, making sudden decreases in blood 
pressure even more severe.5 
The aging nervous system also contributes to altered 
responses to medications in the older adult.6  For instance, an 
older adult’s brain has a diminished reserve of 
neurotransmitters, and therefore has a diminished capacity to 
compensate for changes in response to medications.7  
Psychoactive medications that permeate the blood brain barrier 
may cause increased concentrations of the drug at the nerve 
endings, often manifesting as increased effects even with lower 
doses of medications.8  Increased sensitivity to anti-cholinergic 
medications, such as antihistamines, can lead to drowsiness and 
even major confusion in older adults.9  For this reason, it is 
recommended that any initial prescription for these types of 
medications be prescribed at the lowest dose and, if necessary, 
gradually increased over time to prevent potentially harmful 
side effects. 
PHARMACOKINETICS 
Older adults experience age-related changes that affect 
pharmacokinetics—the manner in which drugs are distributed, 
metabolized, and excreted—predisposing this population to 
possible adverse drug effects.  Absorption of medications is 
altered due to changes within the gastrointestinal system.  Most 
drugs are absorbed through passive diffusion in the small 
intestine; however, oral and gastric absorption of medication 
 
 4.  Id. at 65–66. 
 5.  Id. at 66. 
 6.  Id. 
 7.  Id. 
 8.  Id. 
 9.  Id. 
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also occurs.10  A slowed transit time between the oral cavity and 
small intestine due to decreased peristaltic movement will 
decrease absorption.11  A subset of older adults experience 
achlorhydria, which is a decreased secretion of hydrochloric 
acid.12 Achlorhydria is often found in those who have had peptic 
ulcer disease or previous gastric surgery.13  In addition, many 
geriatric patients undergo long-term treatment with proton-
pump inhibitors and histamine-2 blockers for gastroesophageal 
reflux disease (GERD), more commonly called heartburn, which 
can potentially decrease the absorption of drugs.14 
The storage and distribution of drugs in older adults 
significantly affects sensitivity and response to medications.  
Older adults have a decrease in total body water and lean 
muscle mass, and a corresponding increase in body fat 
percentage.15  Therefore, hydrophilic (water-loving) medications 
have a smaller volume of distribution, and greater effects at 
smaller doses.16  This alteration indicates the need to prescribe 
the lowest possible medication dose because therapeutic 
responses will be seen sooner than in younger adults.  Higher 
serum concentrations of hydrophilic medications put the older 
adult at greater risk for experiencing toxic effects.  Similarly, 
medications that are distributed into lean muscle mass also have 
a smaller volume of distribution.17 One example of such a 
medication is digoxin, which slows and strengthens heart 
contractions.  Digoxin has an average distribution volume of 
only three to four liters per kilogram in the geriatric population, 
compared to six to seven liters per kilogram in younger adults.18  
As a result, digoxin toxicity is common and should be carefully 
 
 10.  Id. at 63. 
 11.  Id. 
 12.  Id. 
 13.  Id. 
 14.  See id. 
 15.  Id. 
 16.  Id. 
 17.  Id. 
 18.  Id. at 63–64. 
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monitored in older adult populations.19 
Lipophilic (lipid- or fat-loving) medications pose a unique 
problem to older adults, as these medications have the 
propensity to accumulate in the body and to be stored for longer 
periods of time.20  As the drug accumulates, older adults are 
more likely to experience toxic effects.  Due to this alteration in 
drug distribution, lipophillic benzodiazepines and anti-
psychotics are two classes of medications that pose higher risk in 
the older adult population.21  Many psychotherapeutic agents 
also have longer half-lives, which prolong the effects and can 
result in older adults progressing through stages of drowsiness, 
confusion, delirium, and on to somnolence from the medication 
accumulation.22 
Older adults who have decreased protein stores, such as 
those with hypoalbuminemia, may also experience increased 
drug effects.  A protein-binding drug that is unbound to a body 
protein is the active form of the drug responsible for its effects 
on the body.  Malnourished and frail elders are the most 
susceptible to decreased protein stores and consequent increased 
effects from medications.23  Two protein bound medications are 
warfarin (blood thinner) and phenytoin (anti-seizure).24  
Warfarin is a commonly prescribed anti-coagulant used to 
prevent blood clots from forming after heart attacks, valve 
replacements, and rapid heart rates, or to prevent existing clots 
from growing.  Accumulation of this medication can cause 
serious bleeding; therefore, the dosage must be carefully 
monitored during the entire course of therapy, and all clinicians 
involved in treatments need to be informed of its use.25 
The liver is one of the major body organs involved in the 
 
 19.  See, e.g., Kristen Cook & James E. Tisdale, Cardiovascular, in FUNDAMENTALS 
OF GERIATRIC PHARMACOTHERAPY 121, 121, 147 (Lisa C. Hutchison & Rebecca B. 
Sleeper eds., 2010). 
 20.  Hutchinson, supra note 1, at 64. 
 21.  Id. (citation omitted). 
 22.  See id. 
 23.  Id. 
 24.  Id. 
 25.  See, e.g., Cook & Tisdale, supra note 19, at147.  
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metabolism or breakdown of drugs in the body.  The liver in 
older adults is often smaller in size and has decreased blood 
flow.26  Drugs that are highly metabolized through the liver 
must be prescribed at lower dosages because greater 
concentrations will be available in the blood stream.27 
Decreased excretion of drugs is another age-related change 
that must be considered by clinicians prescribing for the older 
adult.  Kidney size and renal blood flow are reduced in the older 
adult, in addition to decreased functioning of the kidney’s 
filtration units, the glomeruli.28  Direct measurement of the 
glomerular filtration rate (GFR) is not routinely measured in 
clinical practice because it requires a 24-hour urine collection 
and processing.29  Therefore, it is possible that kidney function in 
some older adults may be more diminished than estimated.  The 
usual standard of practice is to use an estimated GFR that can be 
found with a simple blood test, or to determine creatinine 
clearance with the Cockcroft-Gault equation.30  The use of the 
Cockcroft-Gault equation may be problematic for those with low 
muscle mass as the equation may not adequately take into 
account the decreased rate of tubular secretion in proportion to 
the decreased number of nephrons in the smaller kidney of the 
older adult.31  Adults with compromised kidney function carry a 
high risk of experiencing increased effects of medications since 
they circulate for a longer period of time in the blood before 
being filtered out.  A number of prescription drugs have specific 
guidelines for renal dosing in those with varying degrees of 
known renal impairment.32 
 
 26.  Hutchison, supra note 1, at 64. 
 27.  Id. 
 28.  See id. at 65. 
 29.  Id. 
 30.  Id. 
 31.  Id. 
 32.  For an example of various drugs’ necessary dosage adjustments for 
patients with decreased renal function, see David F. McAuley, Renal Dosing 
Database, GLOBAL RPH, http://www.globalrph.com/renaldosing2.htm (last visited 
Feb. 13, 2012). 
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POLYPHARMACY 
Polypharmacy, or the use of many medications, is a 
common issue in geriatric therapeutics because of the frequency 
of multiple chronic diseases that require multi-drug regimens.  
Additionally, there is a plethora of what are known as “me-too” 
drugs—medications that are often more expensive than their 
predecessors but offer no additional treatment benefit, and 
which generally have not been tested with frail older adults with 
co-existing illnesses.33  The fact that older adults are frequently 
excluded from clinical drug trials further contributes to the lack 
of knowledge and awareness of polypharmacy effects in the 
geriatric population.34 
It cannot be overlooked that many chronic diseases such as 
hypertension, congestive heart failure, chronic obstructive 
pulmonary disease, and diabetes often co-exist and require 
multi-drug regimens for therapeutic outcomes.  The 
proliferation of some new medications has contributed to 
improvements in management options for these illnesses.35 
Coupled with the fact that older adults are more at risk of 
developing chronic diseases as they age, it can be argued that 
polypharmacy can be a necessity.36 
Unnecessary polypharmacy, however, can occur due to a 
preventable phenomenon known as “prescribing cascade.”  This 
results from prescribing one medication for one indication, such 
as a non-steroidal anti-inflammatory drug (NSAID) for arthritis 
pain, which then results in a prescription for a proton-pump 
inhibitor when gastric irritation occurs from NSAID use.37  
 
 33.  See Randall S. Stafford et al., New but Not Improved? Incorporating 
Comparative-Effectiveness Information into FDA Labeling, 361 N. ENG. J. MED. 1230, 
1231 (2009). 
 34.  See Jerry Avorn, Medication Use in Older Patients: Better Policy Could 
Encourage Better Practice, 304 JAMA 1606, 1606–07 (2010). 
 35.  Diane Mahoney et al., Preventing Drug-Drug Interactions Among Older 
Adults: Guidelines and Clinical Application, 3 AM. J. NURS. PRAC. 7, 7 (1999). 
 36.  See, e.g., Noel H. Ballentine, Polypharmacy in the Elderly: Maximizing Benefit, 
Minimizing Harm, 31 CRITICAL CARE NURS. Q. 40 (2008). 
 37.  Id. at 44. 
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Clinicians must be vigilant to avoid treating one drug symptom 
with another drug that also produces side effects resulting in 
more drug therapies for symptoms that are not disease-
induced.38  Multiple prescribers from multiple settings also 
increase the likelihood of polypharmacy.  As patients transition 
among generalists and specialists and through primary care, 
acute care, rehabilitation, and long-term care settings, redundant 
medications can occur.  A medication review to reduce 
redundant and unnecessary medications is recommended at 
every transfer point in care. 
ADVERSE DRUG EVENTS 
Adverse drug events (ADEs) include both harm caused by 
the drug, such as an adverse drug reaction (ADR) or overdose, 
and harm from the use of the drug.39  Unfortunately, ADRs can 
occur within normal dosing ranges and regular usage.  As stated 
previously, older adults are more susceptible to ADEs due to 
changes related to normal aging.  Because older adults are more 
likely to experience chronic diseases that require multi-
prescription drug regimens, this population is also more likely 
to experience side effects and interactions between multiple 
medications.  ADEs are a significant cause of morbidity and 
mortality in the older adult population, as well as one of the top 
reasons for admission to the hospital.40  Drug-drug interactions 
account for many incidences of ADEs and drug toxicities.41 
Identifying ADEs in the older adult poses an even more 
difficult problem because older adults often present with vague 
symptoms, such as confusion or fatigue, which may actually be 
 
 38.  See Diane Feeney Mahoney, Innovations in Clinical Practice (ICP) Fast Fact 
Sheet, Geriatric Prescribing Guidelines, NAT’L GERONTOLOGICAL NURS. ASS’N, (Jan. 
2004) (on file with Nat’l Gerontological Nurs. Ass’n.). 
 39.  Jonathan R. Nebeker et al., Clarifying Adverse Drug Events: A Clinician’s 
Guide to Terminology, Documentation, and Reporting, 140 ANNALS INTERNAL MED. 795, 
797–798 (2004). 
 40.  Ballentine, supra note 36, at 40. 
 41.  See id. at 45; see also Jerry H. Gurwitz et al., The Incidence of Adverse Drug 
Events in Two Large Academic Long-Term Care Facilities, 118 AM. J. MED. 251 (2005). 
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signs of a serious ADE.  Additionally, the ADE may present long 
after the patient has started taking the drug because of the age-
related changes discussed above or the addition of a new acute 
condition.  Estimates indicate there are approximately 760,000 
preventable ADEs annually in nursing homes resulting mainly 
from complications of polypharmacy due to indefinite use of 
medications beyond their original indications.42 
Medication errors refer to mishaps that occur during 
prescribing, transcribing, dispensing, or administering a drug.  
Not all errors result in ADEs, but they may be classified as “near 
misses” or potential for ADE when they are stopped prior to 
harm.  Medication errors are more common than ADEs, but 
result in harm less than 1% of the time.43  ADRs and harmful 
medication errors should be documented in the medical record 
and pharmacy and therapeutic committee reports.  Suspected 
severe ADRs should be reported to the FDA’s MedWatch 
program. 
SUBOPTIMAL PRESCRIBING 
Suboptimal prescribing refers to overuse, misuse, or 
underuse of medications.44  It can be argued that suboptimal 
prescribing can also refer to using medications as the initial 
treatment for a condition, rather than considering appropriate 
non-drug alternatives.45  In 1991, Dr. Mark Beers and colleagues 
published a listing of medications that an expert panel 
consensus deemed inappropriate for frail older adults residing 
in nursing homes.46  In 1997, the listing was expanded to include 
medication therapy in all patients over age sixty-five.47  Beers’ 
 
 42.  See Gurwitz et al., supra note 41, at 256. 
 43.  Nebeker et al., supra note 39, at 797. 
 44.  See Gurwitz et al., Improving Medication Prescribing and Utilization in the 
Nursing Home, 38 JAGS 542, 542 (1990). 
 45.  Mahoney et al., supra note 35, at 11. 
 46.  Mark H. Beers et al., Explicit Criteria for Determining Inappropriate Medication 
Use in Nursing Home Residents, 151 ARCHIVES INTERNAL MED. 1825 (1991). 
 47.  Mark H. Beers, Explicit Criteria for Determining Potentially Inappropriate 
Medication Use by the Elderly: An Update, 157 ARCHIVES INTERNAL MED. 1531, 1532 
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criteria deemed a medication inappropriate if its usage and/or 
dosage presented potential risks that outweighed potential 
benefits.48  The list offers straightforward guidelines for geriatric 
prescribing, identifying both harmful medications and 
inappropriate dosages.  Beers’ list was updated again in 2003.49  
The Centers for Medicare and Medicaid Services (CMS) adopted 
this list as a guideline for nursing home regulation.50  Wise 
prescribers and consultant pharmacists also apply the Beers 
listing in practice.  Still, in a 2005 study of 157,517 adults over 
age sixty-five enrolled in health maintenance organizations 
(HMO), it was found that five percent of participants were 
prescribed at least one out of the eleven medications in the 
“always avoid” category of Beers’ list.51  In 2010, researchers 
found mixed results in a review of eighteen interventions that 
employed a variety of approaches to improving suboptimal 
prescribing in nursing homes.52  Thus, despite the existence and 
acceptance of guidelines pertaining to prescribing for the older 
adult, suboptimal prescribing continues to be an issue that 
requires the careful attention of health care practitioners.53 
Similarly, attention is turning to the enhancement of 
palliative care efforts by relieving pain and increasing comfort 
for nursing home residents with advanced dementia.  By expert 
panel consensus, medications have been identified and deemed 
“never appropriate” for treatment of advanced dementia when 
the goal of treatment is palliative care.54 And yet, in a recent 
 
(1997). 
 48.  Id.  
 49.  Donna M. Fick et al., Updating the Beers Criteria for Potentially Inappropriate 
Medication Use in Older Adults, 163 ARCHIVES INTERNAL MED. 2716 (2003). 
 50.  Ann S. Luggen, Pharmacology Update: Inappropriate Prescribing in the Long-
Term Care Setting, 26 GERIATRIC NURS. 233 (2005). 
 51.  Steven R. Simon, et al., Potentially Inappropriate Medication Use by Elderly 
Persons in U.S. Health Maintenance Organizations, 2000–2001, 53 JAGS 227, 228, 230 
(2005). 
 52.  Zachary A. Marcum et al., Interventions to Improve Suboptimal Prescribing in 
Nursing Homes: A Narrative Review, 8 AM. J. GERIATRIC PHARMACOTHERAPY 183, 183 
(2010). 
 53.  See Hedva Barenholtz Levy et al., Beyond the Beers Criteria: A Comparative 
Overview of Explicit Criteria, 44 ANNALS PHARMACOTHERAPY 1968, 1968 (2010). 
 54.  See Holly M. Holmes et al., Integrating Palliative Medicine into the Care of 
13.1_(2)MAHONEY.PRINT.DOC (DO NOT DELETE) 2/29/2012  8:13 AM 
42 MARQUETTE ELDER’S ADVISOR [Vol. 13 
study of nursing home residents with advanced dementia, 
thirty-seven percent received at least one of the medications 
considered never appropriate, with modest reductions in dosage 
or usage occurring only during the last week of life.55  In a 
separate study, forty-four percent of nursing home residents 
who reported pain received neither standing orders for pain 
medication nor special services for pain management.56  Non-
white residents and those with dementia were less likely to 
report or show signs of pain than white residents or those 
cognitively intact, respectively.57  Efforts are underway to 
improve pain management.  In 2009, CMS promulgated F309, a 
guideline pertaining to quality of care related to pain assessment 
and management.58  Additionally, the Center for Nursing 
Excellence in Long-term Care now offers free access to their 
website’s evidence-based tools and best practices for assessment 
and management of pain in older adults—an invaluable tool for 
nurses who work in nursing homes.59  Future research is 
warranted to determine the effects of these approaches. 
GERIATRIC PRESCRIBERS AND INFLUENCES ON THEIR 
TREATMENT DECISION MAKING 
With the burgeoning aging population, the need for clinicians 
with specialized training in geriatric prescribing is more relevant 
than ever.  However, specialized training in geriatric prescribing 
remains a critical piece still missing from many medical, dental, 
 
Persons with Advanced Dementia: Identifying Appropriate Medication Use, 56 JAGS 1306, 
1306 (2008). 
 55.  Jennifer Tjia et al., Daily Medication Use in Nursing Home Residents with 
Advanced Dementia, 58 JAGS 880, 880 (2010). 
 56.  Manisha Sengupta, Prevalence and Management of Pain, by Race and Dementia 
Among Nursing Home Residents: United States, 2004, U.S. DEP’T HEALTH & HUM. 
SERV., NCHS DATA BRIEF, no. 30, Mar. 2010, at 2. 
 57.  Id. at 4. 
 58.  CMS Releases Pain Management Guidelines for Nursing Homes Under F309, 
HCPRO (Apr. 16, 2009), http://www.hcpro.com/LTC-231585-4564/CMS-releases-
pain-management-guidelines-for-nursing-homes-under-F309.html. 
 59.  THE CENTER FOR NURSING EXCELLENCE IN LONG-TERM CARE, 
http://www.centerfornursingexcellence.org (under “Resources” click “Geriatric 
Pain Website”).  
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and osteopathic education programs in the United States.60  
Required courses in geriatrics are absent or limited in most 
medical schools, and many trainees emerge into practice with a 
poor understanding of pharmacotherapeutics in older adults.61  
Formal medical training continues to emphasize the mechanisms 
of disease and diagnostics, with inadequate attention paid to the 
nuances of prescriptive and non-prescriptive therapies for older 
adults. 
The newest prescriber group is advanced practice registered 
nurses (APRNs), which encompasses more than 150,000 nurse 
midwives, psychiatric or mental health clinical specialists, and 
nurse practitioners (NPs).  In the nursing home setting, most 
NPs are certified as either adult and/or gerontological NPs.  NPs 
receive additional education in their specialty, usually at the 
Master’s or Doctoral level, and after passing a national 
certification exam they are authorized per individual state 
regulations to practice and prescribe.62 
Numerous studies have documented the effectiveness of 
NPs’ management of complex patients in a variety of clinical 
settings.  NPs are educated to examine the geriatric patient as a 
whole person, that is, not only looking at an individual’s medical 
information, but also their social, psychological, and mental 
health and health behaviors as well as economic status and 
cultural beliefs.  Initial research on NP prescribers found they 
were significantly less likely than physicians to write a 
suboptimal prescription for a condition when a non-drug 
alternative or lifestyle recommendation was considered more 
appropriate.63  When the first nurse-developed guidelines for 
geriatric prescribing were published in 1999, practitioners were 
instructed to first consider treatment by a non-drug alternative 
 
 60.  Avorn, supra note 34, at 1606. 
 61.  Id.  
 62.  For a state-by-state comparison of NP legislation, including NP licensure 
requirements, see the annual Pearson Report.  Linda J. Pearson, The Pearson Report, 15 
AM. J. NURSE PRAC., Mar. 2011, available at http://www.pearsonreport.com. 
 63.  See Diane Feeney Mahoney, Appropriateness of Geriatric Prescribing Decisions 
Made by Nurse Practitioners and Physicians, 26 J. NURS. SCHOLARSHIP 41 (1994). 
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therapy and assess whether new symptoms were attributable to 
present drug therapies.64  The current version offers four 
recommendations prior to introducing a new drug therapy and 
nine recommendations to assist in balancing the risks and 
benefits and educating patients and their caregivers about their 
medications.65 
Recent research suggests that APRNs in primary care are 
increasingly targeted by pharmaceutical promotions, and some 
APRNs reflect physicians’ positive attitudes towards marketing 
efforts by favoring brand name drugs when lower cost generics 
are available.66  This research was conducted with NPs from 
primarily ambulatory settings.  A review of the research 
literature found only one study of gerontological NPs’ 
prescribing patterns; this study reported that gerontological 
NPs’ prescribing practices were more influenced by practice 
setting than by their age, education, and years of practice.67  
Although inappropriate prescribing according to the Beers 
criteria was minimal, it was more likely to occur in ambulatory 
office-based settings rather than long-term care settings.68  The 
reasons for this discrepancy were speculative.  Given the lack of 
clarity about influences on NPs’ choice of drug therapy, 
gerontological NPs in attendance at a national meeting were 
recruited to participate in one of two focus groups conducted to 
increase understanding about the influence of their practice 
setting and other factors on their prescribing patterns.69  Several 
key influences were identified. 
Foremost the NPs acknowledged that their practice setting, 
 
 64.  Mahoney et al., supra note 35, at 12; Mahoney, supra note 38. 
 65.  Mahoney, supra note 38. 
 66.  Elissa C. Ladd, Diane Feeney Mahoney & Srinivas Emani, “Under the 
Radar”: Nurse Practitioner Prescribers and Pharmaceutical Industry Promotions, 16 AM. J. 
MANAGED CARE e358 (2010). 
 67.  Laurie Kennedy-Malone et al., Prescribing Patterns of Gerontological Nurse 
Practitioners in the United States, 20 J. AM. ACAD. NURS. PRAC. 28, 31‒32 (2008). 
 68.  Id. at 33. 
 69.  Diane Feeney Mahoney & Elissa Ladd, More than a Prescriber: Gerontological 
Nurse Practitioners’ Perspectives on Prescribing and Pharmaceutical Marketing, 31 
GERIATRIC NURS. 17 (2010). 
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including the type of patient served and the degree of autonomy 
they had in choosing medications, made a difference in their 
prescribing patterns.70  Office-based NPs were constrained 
beyond the usual practice regulations by the office drug 
protocols established by their employing physician(s).71  Overall, 
NPs took into consideration whether the patient was at home 
alone and able to independently take and remember their 
medications, or whether there were other caregivers who could 
reliably administer medications.72  They were knowledgeable 
about the affordability and insurance coverage for medications, 
and sensitive to ways to enable adherence to therapies.73  NPs 
had to educate and counsel families and patients who 
demanded drugs advertised on television, mistakenly believing 
the drugs would rectify chronic medical problems.74  Assessing 
drug necessity versus using a nondrug alternative was every 
NP’s starting point, with clear sensitivity to geriatric drug 
dosing, polypharmacy, and pharmacokinetics.75  The nurses 
participating in the study highlighted the geriatric dilemma 
inherent in evidence-based practice recommendations that are 
based on “research [that] did not include geriatric patients, 
generic drugs, or attention to quality-of-life issues.”76  Another 
dilemma presented itself when their supervising physician’s 
protocol did not follow evidence-based guidelines and therefore 
precluded the NPs from prescribing the “better” agent.77  
Attending to drug reimbursement issues took considerable time 
and advocacy with insurers and in many cases the NPs 
recommended the commercial four-dollar drug plans because of 
better affordability and improved likelihood of purchase.78 
When asked about pharmaceutical marketing and drug 
 
 70.  See id. at 21. 
 71.  Id. 
 72.  Id. 
 73.  Id. 
 74.  Id. at 21‒22. 
 75.  See id. at 20. 
 76.  Id.  
 77.  Id. at 21. 
 78.  Id. 
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detailing, the NPs viewed those activities as providing 
information but not education.79  Clear skepticism about drug 
representatives presenting biased information was prevalent. 
Concerns also arose about prescribers being pressured to 
prescribe a certain drug because a pharmaceutical company 
gave the institution a “good deal” on purchasing it.80  When the 
patients transitioned into a facility that did not get the same 
good deal, they had to be switched to that facility’s offerings.81  
The NPs also identified several “costs” associated with free 
samples including an unintended impression on patients that 
brand name drugs were superior to generics.82  In long-term care 
facilities, medications are provided by pharmacies in thirty-day 
packs.  The NPs noted it was common to try several medications 
to find the best one for a patient’s particular situation.  When the 
drug was changed after a week-long trial, many facilities 
discarded the remaining medication as waste. 
NPs’ preferred sources of drug information, after the 
professional drug literature, were geriatric physicians and 
consulting geriatric pharmacists.83  The latter were most 
desirable to aid in complex cases with multi-drug, multi-disease 
geriatric patients experiencing compromised renal and liver 
functioning.84  Comments portrayed the NPs role as multi-
faceted, offering more than just being a prescriber.  “Lifestyle 
counseling, care coordination, drug reviews and reductions, 
quality-of-life considerations, family and patient teaching, and 
nondrug treatment alternatives all remained equally important 
aspects” of the NPs’ offerings.85  Therapy was tailored according 
to the “patients’ biophysical, psychological, and economic needs 
with an involvement in the interplay of geriatric care issues not 
 
 79.  Id.at 22. 
 80.  Id. at 23. 
 81.  Id. 
 82.  See id. 
 83.  Id. at 24. 
 84.  See id. at 23. 
 85.  Id. at 26. 
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typically addressed by primary care physicians.”86  Nonetheless, 
influences on NPs’ ability to prescribe and practice according to 
the full scope of practice were identified as limitations to 
improving geriatric care.   
STATE AND FEDERAL REGULATIONS 
The major external influences on prescribing in long-term 
care are federal and state regulation. The Omnibus Budget 
Reconciliation Act (OBRA), implemented in 1990, requires that 
the facility provide each patient with care that will enable the 
patient to “attain or maintain the highest practicable physical, 
mental, and psychosocial well-being . . . .”87  Since then, it has 
been the U.S. Centers for Medicare and Medicaid Services’ 
(CMS) responsibility for overseeing the implementation of this 
legislation. 
For nursing homes to be certified to participate in the 
Medicare and Medicaid programs, pharmacists are required to 
review the appropriateness of residents’ medications on a 
monthly basis, and to recommend changes to providers when 
indicated.  Additionally, each facility is required to complete the 
Minimum Data Set (MDS), a standardized tool to monitor and 
track residents’ functional abilities and progression or decline in 
relation to their diagnoses and treatments.88  Registered nurses 
or case managers hired by the facility are responsible for 
completing the MDS for each resident on a quarterly basis, or 
whenever there is a change in the resident’s condition.  Facilities 
are subject annually to unannounced external reviews by CMS 
sponsored state surveyors who assess compliance to regulations, 
identify deficiencies, and mandate improvements if necessary.89 
 
 86.  Id. 
 87.   42 U.S.C. § 1395i-3(b)(2) (section remains unchanged from enactment in 
1988 to present). 
 88.  See generally Nursing Home Quality Initiatives, CTRS. MEDICARE & MEDICAID 
SERV., http://www.cms.gov/NursingHomeQualityInits (last visited Feb. 22, 2012). 
 89.  Posting of facilities’ ratings can be found at Nursing Home Compare, 
http://www.Medicare.gov/NHcompare (last visited Feb. 22, 2012). 
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ADVOCATING TO PROMOTE MORE APPROPRIATE PRESCRIBING 
IN LONG-TERM CARE 
REDUCE THE IMPACT OF PHARMACEUTICAL MARKETING ON 
PRESCRIBERS. 
The pharmaceutical industry spent $20.5 billion in 2008 to 
promote name brand prescription drugs.90  Of this, $12 billion 
was spent to detail physicians, NPs, and physician assistants; 
$3.4 billion to sponsor professional meetings and events; $400 
million to advertise in professional journals; and $4.7 billion to 
advertise direct-to-consumers (DTC).91 
The Institute of Medicine (IOM) issued a report that 
addressed the role of funding from pharmaceutical and medical 
device companies to support professional continuing education 
programs.92  The report stated that such funding inherently 
creates conflicts of interest and recommends redesigning 
continuing education in the health professions to reduce 
dependency on these industries.93  From the federal legislative 
perspective, physician payment sunshine provisions were 
included in the Patient Protection and Affordable Care Act of 
2009 (PPACA or ACA), which was signed into law on March 23, 
2010 but implemented only recently.94  These sunshine 
provisions mandate the disclosure of gifts and payments over 
ten dollars to physicians and teaching hospitals by 
“manufacturers,” including pharmaceutical and medical device 
companies.95 
 
 90.  CONG. BUDGET OFF., ECON. & BUDGET ISSUE BRIEF, PROMOTIONAL 
SPENDING FOR PRESCRIPTION DRUGS  2 (Dec. 2, 2009). 
 91.  Id. at 1–2. 
 92.  INST. MED. NAT’L ACAD., REDESIGNING CONTINUING EDUCATION IN THE 
HEALTH PROFESSIONS 4, 69–72 (2009), available at http://www.iom.edu/Reports/2009/ 
Redesigning-Continuing-Education-in-the-Health-Professions.aspx (download free 
full report in right navigation pane). 
 93. Id. at 4, 69–72. 
 94. 42 USC § 1320a-7h (2009).  
 95. See id. at § 1320a-7h (e)(10)(B)(i). These disclosure reports should be publicly 
available online by September 30, 2013. Id. at § 1320a-7h (c)(1)(C). 
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At the state level, Vermont previously placed a ban on 
pharmaceutical companies providing free meals96, and 
Massachusetts limits meals to purchases in a hospital setting and 
requires disclosure of any gift greater than fifty dollars.97  The 
Harvard affiliated hospitals recently enacted stringent policies 
on their staff, including clinical researchers who were not 
addressed under the legislation.  This movement has caused a 
backlash among businesses, including hospitals, that benefited 
from pharmaceutical-sponsored events and which now claim 
loss of critical revenue during an economic recession.  
Lawmakers sought unsuccessfully to repeal the Massachusetts 
bill.98 
The Pew Prescription Project, created by the Pew Charitable 
Trusts, is an initiative “to promote consumer safety through 
reforms in the approval, manufacture, and marketing of 
prescription drugs, as well as through initiatives to encourage 
evidence-based prescribing.”99  The Project conducted a review 
of the published studies on academic detailing, or individual 
prescriber education programs to physicians, which provide 
unbiased drug information and drug cost comparisons.100  While 
the potential for improved care and cost savings existed, most 
programs were limited by short-term funding that hampered 
longer-term behavioral changes in prescribing practices.101 
 
 96. 18 VT .STAT. ANN. tit. 18 §§ 4631a(a)(5)(B), (b)(1) (2012). 
 97. Jacob Goldstein, Massachusetts Bans Industry Gifts to Docs, WALL ST. J. 
HEALTH BLOG, (Mar. 12, 2009, 10:21 AM), http://blogs.wsj.com/health/2009/03/12/ 
massachusetts-bans-industry-gifts-to-docs/. 
 98.  Katherine Hobson, Lawmakers Propose Banning the Mass. Physician Gift Ban, 
WALL ST. J. HEALTH BLOG, (June 25, 2010 1:01 PM), 
http://blogs.wsj.com/health/2010/06/25/lawmakers-propose-banning-the-mass-
physician-gift-ban/; Katherine Hobson, Follow-Up: Massachusetts Gift Ban Won’t Be 
Repealed, WALL ST. J. HEALTH BLOG, (Aug 2, 2010, 3:58 PM), 
http://blogs.wsj.com/health/2010/08/02/follow-up-massachusetts-gift-ban-wont-be-
repealed/. 
 99.  About Us: Project Overview, PEW PRESCRIPTION PROJECT, 
http://www.prescriptionproject.org/about (last visited Feb. 24, 2012). 
 100.  Cost-Effectiveness of Prescriber Education (“Academic Detailing”) Programs, 
PEW PRESCRIPTION PROJECT REPORT 1 (Mar. 12, 2008), available at http://www. 
PrescriptionProject.org/tools/initiatives_reports/files/Final-AcademicDetailing_Cost 
Effectiveness_Analysis_3-12-2008_CB.pdf (last visited Feb. 24, 2012). 
 101.  See id. at 4‒5. 
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CONTINUE THE USE OF PHARMACEUTICAL PENALTY FUNDS TO 
SUSTAIN RESEARCH AND DEMONSTRATION PROJECTS THAT 
IMPROVE MEDICATION DECISION MAKING AND REDUCE DRUG 
COSTS. 
Pharmaceutical penalty funds can be created when drug 
manufactures are ordered to pay substantial fines for violating 
laws that protect consumers. 
On May 13, 2004, Warner-Lambert, a division of Pfizer, 
Inc., entered into an Assurance of Voluntary 
Compliance/ Discontinuance with the Attorneys 
General of 50 States and the District of Columbia to 
settle allegations that Warner-Lambert conducted an 
unlawful marketing campaign for the drug Neurontin® 
that violated state consumer protection laws.  Among 
other things, the settlement provides for a $21 million 
Consumer and Prescriber Education grant program to 
be administered by a Special Committee of State 
Attorneys General pursuant to an Oregon Court 
Order.102 
Through this endeavor, several key initiatives have been 
developed to increase prescriber’s skepticism about drug 
promotional activities and use of evidence-based drugs. 
On the consumer education side, Consumers Union 
implemented Best Buy Drug reports to provide free web-based, 
unbiased descriptions and comparisons among common 
medications including their brand and generic costs.103  After its 
creation, the program was featured in Consumers Union’s 
publication and highlighted the most common drugs with 
generic savings as well as national locations for four dollar 
generics.104  This information is critical for consumers because of 
 
 102.  Consumer & Prescriber Grant Program, http://www.consumerprescriber 
grantprogram.org/ (last visited Feb 24, 2012); In the matter of Warner-Lambert 
Company LLC, Assurance of Voluntary Compliance, ¶ 27, available at 
http://www.consumerprescribergrantprogram.org/files/Assurance_of_Voluntary_ 
Compliance.pdf 
 103.  Best Buy Drug Reports, CONSUMER RPTS. BEST BUY DRUGS, 
http://www.consumerreports.org/health/best-buy-drugs/index.htm. 
 104.  Best Buy Drugs, CONSUMER REPORTS MAGAZINE, Mar. 2011, at 24‒27, 
available at http://www.consumerreports.org/cro/magazine-archive/2011/march/ 
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the great number of “me-too” drugs.  There is often a lack of 
evidence available comparing the “me-too” drugs to their 
predecessors because higher profits results from developing and 
marketing more expensive new drugs.  This profit motive has 
been seen in the advent of new selective-serotonin reuptake 
inhibitors (SSRIs), despite the fact that older, generic drugs in 
this class are often better and cheaper alternatives.105  As 
Consumer Reports noted, many heartburn sufferers now go 
immediately to powerful proton pump inhibitors (PPIs) when 
studies have shown sixty-nine percent of them do not need PPIs, 
but could be treated by lifestyle changes such a modifying their 
eating habits or using inexpensive antacids.106  Should a PPI be 
necessary, consumers can save $184 a month by using a generic 
omeprazole instead of Nexium® (esomeprazole magnesium).107  
Successful efforts to provide unbiased objective drug 
information to consumers and prescribers should be sustained 
and financially supported by pharmaceutical fines. 
SUPPORT THE INSTITUTE OF MEDICINE’S (IOM) 
RECOMMENDATIONS ON NP PRACTICE. 
The first recommendation of the IOM is “Nurses should 
practice to the full extent of their education and training.”108  The 
practice rules that define the NPs’ permissible activities, 
including prescriptive authority, vary widely because licensing 
and regulations vary among the states.  A nurse can or cannot 
prescribe certain classes of drugs by virtue of where he or she 
resides and whether the NP has a supervising or collaborative 
relationship with physicians.  Thus, the NPs’ skillset in the 
marketplace is limited not by their education, credentialing, or 
 
health/ best-buy-drugs/overview/index.htm. 
 105.  See id. (click “Depression” in navigation pane). 
 106.  Id. (click “Heartburn” in left navigation pane). 
 107.  See id.  
 108.  INST. MED. NAT’L ACAD., THE FUTURE OF NURSING: LEADING CHANGE, 
ADVANCING HEALTH 2 (2010), available at http://www.iom.edu/Reports/2010/The-
Future-of-Nursing-Leading-Change-Advancing-Health.aspx (download free full 
report in right navigation pane) [hereinafter “THE FUTURE OF NURSING”]. 
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practice competencies, but by the unique state laws and office 
policies where they work.  The IOM recommends that state 
scope of practice laws be reformed to remove unduly restrictive 
barriers to NP practice.109  Broad based coalitions began 
developing in 2011 to pursue changes in restrictive state and 
federal legislation over the NP scope of practice as well as anti-
competitive and anti-trust laws.  Support for these endeavors 
will remove undue restrictions on NP services and bring more 
NP specialists caring for older adults into nursing homes. 
ADDRESS THE ISSUES RAISED BY THE NPS IN LONG-TERM CARE. 
NPs advocate for increased access to gero-psychiatric 
prescribers—especially consultant geriatric pharmacists—and 
coverage for remote consultations and new electronic ways of 
communicating with prescribers.  NPs also support reductions 
in drug costs and drug waste.  Most pharmacies dispense in 30-
day quantities because prescription drug plans pay for 30-day 
supplies; however, recent legislative changes in Medicare Part D 
will enable beneficiaries in long-term care facilities to have drugs 
dispensed in 7-day or fewer quantities, thereby encouraging 
titration and reducing waste from unused and costly 
medications.  If drug deals exist, geriatric advocates should 
pursue equitable provisions for consumers such as bulk buying 
opportunities for families or nursing home collectives, and the 
use of evidence-based, lower cost generic drugs when possible. 
ADVOCATE FOR ELECTRONIC HEALTH RECORDS THAT OFFER 
MEANINGFUL DRUG THERAPY REVIEWS AND MEDICATION 
TRACKING ACROSS THE TRANSITIONS IN CARE SETTINGS. 
As new technologies move into health care and long-term 
care, providers and the public need to demand programs that 
extend beyond administrative record keeping and actually carry 
the potential to improve the quality of care.  Prescribers should 
 
 109.  Id. at 1. 
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have access to in-house programs that conduct preliminary drug 
reviews, link to relevant guidelines, and incorporate 
comparative drug cost and efficacy data.  These programs 
should offer online geriatric pharmacy consultations and export 
and import data when the patient transitions across other health 
care settings.  In the future, long-term care can benefit from the 
development of a device similar to an “IBM Watson”110 for 
nursing home therapeutics.  This device would input individual 
data, weigh the relevant factors, and provide the cost-benefit 
scenarios for the appropriate range of therapeutic options.  Until 
then, all providers have critical roles to play in ensuring the 
welfare and safety of older adults. 
 
 110.  For information about IBM Watson and how this technology may be 
applied in the healthcare field, see the video clip at Healthcare, IBM WATSON, 
http://www.ibm.com (under Popular Links, click Watson > Watson for a Smarter 
Planet > Industry Perspectives > Healthcare). 
